22072-07-7

Usage

Uses

Used in Cardiology:
7-CHLORO-4-N,N-DIMETHYLAMINO-QUINOLINE is used as an antiarrhythmic medication for the treatment and prevention of various types of irregular heartbeats, such as atrial fibrillation, ventricular arrhythmias, and supraventricular tachycardia. It is valued for its ability to stabilize the heart's electrical activity, thereby helping to maintain a regular rhythm.
Despite its therapeutic benefits, 7-CHLORO-4-N,N-DIMETHYLAMINO-QUINOLINE requires careful monitoring due to its potential for serious side effects, including lung and thyroid problems, liver toxicity, and skin discoloration. It is essential for healthcare professionals to balance its efficacy with the necessary precautions to ensure patient safety during treatment.

InChI:InChI=1/C11H11ClN2/c1-14(2)11-5-6-13-10-7-8(12)3-4-9(10)11/h3-7H,1-2H3

Upstream product

• 680-31-9 N,N,N,N,N,N-hexamethylphosphoric triamide 
• 86-98-6 4,7-dichloroquinoline 
• 124-40-3 dimethyl amine 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 1258454-22-6 N,N-dimethyl-7-N-[4-(trifluoromethoxy)phenyl]quinoline-4,7-diamine 

Relevant academic research and scientific papers

A versatile method for the synthesis of fluorine-containing chloroquine analogues starting from 7-chloro-4-(N,N-dimethylamino)quinoline using nucleophilic N-N, N-S, and N-O exchange reactions

A new synthetic method was developed to access fluorine-containing chloroquine analogues which have unique potentials contributing to the discovery of novel anti-microorganisms. (7-Chloro-3-trifluoroacetylquinolin-4-yl)amines (7), thiols (8), and ethers (9) were easily synthesized in high yields by the trifluoroacetylation of 7-chloro-4-(N,N-dimethylamino)quinoline (6) with 1-trifluoroacetyl-4-dimethylaminopyridinium trifluoroacetate followed by the nucleophilic N-N, N-S, and N-O exchange reactions.

PRMT5 INHIBITORS

The present invention provides a compound of Formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.

Amination of Aromatic Halides and Exploration of the Reactivity Sequence of Aromatic Halides

A base-promoted amination of aromatic halides has been developed using a limited amount of dimethylformamide (DMF) or amine as an amino source. Various aryl halides, including F, Cl, Br, and I, have been successfully aminated in good to excellent yields. Although the amination of aromatic halides with amines or DMF is usually considered as an aromatic nucleophilic substitution (SNAr) process, and the reactivity of an aromatic halide is F > Cl > Br > I, the reactivity of aromatic halides in this system was found to be I > Br a‰ F > Cl. This protocol also showed a good regioselectivity for multihalogenated aromatics. This protocol is valuable for industrial application due to the simplicity of operation, the unrestricted availability of amino sources and aromatic halides, transition metal-free conditions, no requirement for solvent, and scalability.

Incorporation of a 3-(2,2,2-Trifluoroethyl)-γ-hydroxy-γ-lactam motif in the side chain of 4-aminoquinolines. Syntheses and antimalarial activities

In this paper we report the synthesis and antimalarial properties of two series of fluoroalkylated γ-lactams derived from 4-aminoquinoline as potent chemotherapeutic agents for malaria treatment. These molecules obtained in several steps resulted in the identification of very potent structures with in vitro activity against Plasmodium falciparum clones of variable sensitivity (3D7 and W2) in the range of 19-50 nM with resistance indices in the range of 1.0-2.5. In addition, selected molecules (50, 51, 58, 60, 63, 70, 72, 74, 78, 81, 84, and 87) that are representative of the two series of compounds did not show cytotoxicity in vitro when tested against human umbilical vein endothelial cells up to a concentration of 100 μM. The most promising compounds (82 and 84) showed significant IC50 values close to 26 and 19 nM against the chloroquino-sensitive strain 3D7 and 49 and 42 nM against the multi-drug-resistant strain W2. Furthermore, two model compounds (50 and 70) were found to be quite stable over 48 h at pH 7.4 and 5.2. Overall, our preliminary data indicate that this class of structures contains promising candidates for further study.

Symmetrical bis-quinolinium compounds: New human choline kinase inhibitors with antiproliferative activity against the HT-29 cell line

Studies have been aimed at the establishment of structure-activity relationships that define choline kinase inhibitory and antiproliferative activities of 40 bisquinolinium compounds. These derivatives have electron-releasing groups at position 4 of the q

THE REACTION OF ACTIVATED ARYL AND HETEROARYL DIHALIDES WITH HMPA. A REGIOSELECTIVITY STUDY

A series of activated aryl and heteroaryl dihalides were reacted with HMPA at elevated temperatures.Of the eleven examples studied, all but one reacted in a regioselective manner to give a monohalo-N,N-dimethylamino derivative.